Would you introduce AR targeted therapy if a patient has already been successfully treated with LHRH for low risk, low volume metastatic hormone sensitive prostate cancer?

Most trials of novel AR targeted therapies, started the novel AR blockers within 3 to 6 months of starting standard androgen deprivation therapy. Hence, if that period has passed and the patient is doing well on standard Androgen deprivation therapy, I do not see a need to introduce a novel AR inhib...

Although the time frame associated with the question "successfully treated" is not specified, the trials of the currently approved AR directed therapies abiraterone, apalutamide, and enzalutamide ranged from 3-6 months from the start of ADT for metastatic disease. Needless to say, the issue isn't wh...